Bilfast40 ml

Bilfast 40 ml is indicated for symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.

Non-sedating antihistamines

Bilfast 40 ml is a non-sedative H1 receptor selective antagonist. Its principal effects are mediated via selective inhibition of peripheral H1-receptors. It shows moderate to high affinity for histamine H1-receptors and no affinity for muscarinic, serotonergic, dopaminergic and noradrenergic receptors.

Children between 6 to 11 years: 10 mg mouth dissolving tablet for the symptomatic relief of allergic rhinitis, allergic rhinoconjunctivitis and urticaria. The Mouth dissolving tablet is for oral use only. It should be placed in the mouth. It will disperse rapidly in saliva and can be easily swallowed. Alternatively, the mouth dissolving tablet can be dispersed in a tea spoon of water before being swallowed by the children. The maximum recommended daily dose for children in between 6 to 11 years is 10 mg Bilfast 40 ml mouth dissolving tablet (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken.Adults & adolescents (12 years of age and over): 20 mg tablet once daily for symptomatic relief of allergic rhinitis, urticaria and allergic rhinoconjunctivitis. The maximum recommended daily dose is 20 mg Bilfast 40 ml (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken. 20 mg Bilfast 40 ml tablet (1 tablet) once daily should be swallowed with water on an empty stomach to achieve optimal exposure to Bilfast 40 ml

Adults & adolescents (12 years of age and over): 20 mg tablet once daily for symptomatic relief of allergic rhinitis, urticaria and allergic rhinoconjunctivitis. The maximum recommended daily dose is 20 mg Bilfast 40 ml (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken. 20 mg Bilfast 40 ml tablet (1 tablet) once daily should be swallowed with water on an empty stomach to achieve optimal exposure to Bilfast 40 ml.Children between 6 to 11 years: 10 mg mouth dissolving tablet for the symptomatic relief of allergic rhinitis, allergic rhinoconjunctivitis and urticaria. The Mouth dissolving tablet is for oral use only. It should be placed in the mouth. It will disperse rapidly in saliva and can be easily swallowed. Alternatively, the mouth dissolving tablet can be dispersed in a tea spoon of water before being swallowed by the children. The maximum recommended daily dose for children in between 6 to 11 years is 10 mg Bilfast 40 ml mouth dissolving tablet (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken.Children between 2 to 11 years: 4 ml once daily.

Concomitant intake of Bilfast 40 ml and Ketoconazole or Erythromycin or Diltiazem increased C max of Bilfast 40 ml. The psychomotor performance after concomitant intake of alcohol and Bilfast 40 ml was similar to that observed after intake of alcohol and placebo. Concomitant intake of Bilfast 40 ml and Lorazepam 3 mg for 8 days did not potentiate the depressant CNS effects of Lorazepam.

Bilfast 40 ml is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients of the tablet.

The most commonly reported side effects in clinical trial are headache, dizziness, somnolence and fatigue. These adverse events occurred with a comparable frequency in patients receiving placebo.

There are no adequate or limited amount of data for the use of Bilfast 40 ml in pregnant women and during breast feeding and on the effects on fertility. In case of pregnancy or breast feeding, Bilfast 40 ml should be avoided during pregnancy, unless advised otherwise by a physician.

Co-administration of Bilfast 40 ml and P-glycoprotein inhibitors (e.g. Ketoconazole, Erythromycin, Cyclosporine, Ritonavir or Diltiazem) should be avoided in patients with moderate or severe renal impairment.

In clinical trials, after administration of Bilfast 40 ml at doses 10 to 11 times the therapeutic dose (220 mg as single dose; or 200 mg/day for 7 days) frequency of treatment-emergent adverse events was two times higher than with placebo. The adverse reactions most frequently reported were dizziness, headache and nausea. No serious adverse events and no significant prolongation in the QTc interval were reported.

Keep below 30°C temperature, protected from light and moisture. Keep out of reach of children.

Use in patients with impaired hepatic & renal function: There is no clinical experience in patients with hepatic impairment. Since Bilfast 40 ml is not metabolized and renal clearance is its major elimination route, hepatic impairment is not expected to increase the systemic exposure above the safety margin. Therefore, no dosage adjustment is required in patients with hepatic impairment. No dosage adjustment is required in patients with renal impairment.Geriatrics (>65 years of age): No dosage adjustments are necessary in patients over 65 years.Pediatrics (<6 years of age): The safety and efficacy of Bilfast 40 ml in children under 6 years of age have not been established.

Non-sedating antihistamines

Bilfast 40 ml is a non-sedating, long-acting histamine antagonist with selective peripheral H 1 receptor antagonist affinity and no affinity for muscarinic receptors. Bilfast 40 ml inhibits histamine-induced wheal and flare skin reactions for 24 hours following single doses.

There are no or limited amount of data from the use of Bilfast 40 ml in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, parturition or postnatal development. As a precautionary measure, it is preferable to avoid the use of Bilfast 40 ml during pregnancy. The excretion of Bilfast 40 ml in milk has not been studied in humans. A decision must be made taking into account the benefit of breast-feeding for the child and the benefit of Bilfast 40 ml therapy for the mother.

Efficacy and safety of Bilfast 40 ml in children under 2 years of age have not been established and there is little clinical experience in children aged 2 to 5 years, therefore Bilfast 40 ml should not be used in these age groups.